Boston Scientific Sees Unusually Large Options Volume (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the target of unusually large options trading activity on Wednesday. Investors acquired 65,788 put options on the company. This is an increase of approximately 205% compared to the average daily volume of 21,596 put options.

Boston Scientific Stock Down 1.2%

Shares of NYSE BSX traded down $0.74 during trading on Wednesday, hitting $62.01. The stock had a trading volume of 13,695,060 shares, compared to its average volume of 15,926,059. The firm has a fifty day moving average of $76.37 and a two-hundred day moving average of $90.03. The company has a market capitalization of $92.16 billion, a PE ratio of 31.95, a PEG ratio of 0.97 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific has a 12 month low of $61.24 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the previous year, the company earned $0.70 earnings per share. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.34% of the stock is owned by corporate insiders.

Institutional Trading of Boston Scientific

A number of institutional investors and hedge funds have recently modified their holdings of BSX. Vanguard Group Inc. increased its position in shares of Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares during the last quarter. State Street Corp boosted its holdings in shares of Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after buying an additional 920,495 shares during the last quarter. Capital World Investors boosted its holdings in shares of Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after buying an additional 502,627 shares during the last quarter. Norges Bank bought a new position in Boston Scientific during the fourth quarter valued at about $2,199,395,000. Finally, Morgan Stanley increased its holdings in Boston Scientific by 10.8% during the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after buying an additional 2,246,308 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BSX has been the subject of a number of analyst reports. Stifel Nicolaus reduced their price objective on shares of Boston Scientific from $110.00 to $90.00 and set a “buy” rating for the company in a report on Friday, March 20th. Oppenheimer lowered their target price on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. TD Cowen dropped their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Robert W. Baird cut their price target on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Finally, BTIG Research reissued a “buy” rating on shares of Boston Scientific in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $104.36.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Positive clinical data and regulatory wins that support the company’s minimally invasive portfolio (WATCHMAN FLX, EKOS) and broaden procedure use — supportive for long‑term growth. Are Boston Scientific’s (BSX) New Trial Wins Quietly Redefining Its Minimally Invasive Care Advantage?
• Positive Sentiment: FDA 510(k) clearance for the Asurys Fluid Management System — a near‑term commercial catalyst in endoscopic urology. Boston Scientific wins FDA clearance for fluid management system
• Positive Sentiment: Several analysts/research notes remain constructive (RBC Outperform, Needham reaffirmed Buy, others retain positive views) — provides some support despite recent weakness. Boston Scientific (NYSE:BSX) Earns “Outperform” Rating from Royal Bank Of Canada
• Neutral Sentiment: Longer‑term analyst commentary and equity research pieces highlight BSX as a growth/compounding story, useful context but not immediate drivers. Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Investor pieces and deep‑dive commentary (Seeking Alpha) frame BSX’s transition from hypergrowth to durable compounding — helpful for longer‑term investors but mixed near term. Boston Scientific: From Hypergrowth To Durable Compounding
• Negative Sentiment: Watchman trial data prompted investor concern about stroke outcomes and growth prospects for that franchise; that reaction contributed to a steep share price drop and move to multi‑month/52‑week lows. Boston Scientific Stock Sinks to 2-Year Low. Why Wall Street Is Souring on Trial Data.
• Negative Sentiment: Raymond James downgraded the stock and cut estimates citing weaker trends in U.S. electrophysiology and Watchman — the downgrade amplified selling pressure. Raymond James downgrades Boston Scientific but long-term story remains intact
• Negative Sentiment: Multiple law firms have filed or issued investor alerts about securities‑class‑action claims tied to disclosures between July 23, 2025 and Feb 3, 2026 (lead plaintiff deadline May 4, 2026) — increased litigation risk and headline noise that can pressure the share price. Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.